Preclinical studies with erlotinib (Tarceva)

被引：73

作者：

Akita, RW ^{[1
]}

Sliwkowski, MX ^{[1
]}

机构：

[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 03期

关键词：

D O I：

10.1016/S0093-7754(03)00187-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：15 / 24

页数：10

共 51 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2]

Akita Robert W., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003

[3]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[4] Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3 [J].

Chen, XM ;

Yeung, TK ;

Wang, ZX .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (03) :757-763

[5]

Christensen JG, 2001, CLIN CANCER RES, V7, P4230

[6]

Ciardiello F, 2001, CLIN CANCER RES, V7, P1459

[7] Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype [J].

Damstrup, L ;

Pedersen, MW ;

Bastholm, L ;

Elling, F ;

Poulsen, HS .

INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (01) :7-14

[8] Immunohistochemical comparative analysis of transforming growth factor α, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates [J].

De Miguel, MP ;

Royuela, M ;

Bethencourt, FR ;

Ruiz, A ;

Fraile, B ;

Paniagua, R .

CYTOKINE, 1999, 11 (09) :722-727

[9]

Desai B, 2002, EUR J CANCER, V38, pS63

[10]

EKSTRAND AJ, 1994, ONCOGENE, V9, P2313

← 1 2 3 4 5 6 →